Lorcaserin induces abdominal fat loss with associated improvements of the circulating metabolome/lipidome and no changes in the myostatin–activin–follistatin– IGF ‐1 axes: A 6‐month long randomized placebo‐controlled clinical trial
Diabetes, Obesity and Metabolism · 2026
DOI: 10.1111/dom.70496 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Diabetes, Obesity and Metabolism, 2026. Verfasst von Arantxa Ramirez-Cisneros und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Metabolome, Abdominal Fat, Anti-Obesity Agents, Obesity. Die Arbeit nennt 42 Literaturangaben. Gefördert von: Boehringer Ingelheim, NIH HHS, Massachusetts Life Sciences Center.
Abstract (Originalsprache)
Background
Effective anti‐obesity interventions that preserve lean mass are of increasing clinical significance for optimizing metabolic health. This study investigated whether lorcaserin, a centrally acting weight loss agent, modifies body composition, circulating lipidomic profiles, and muscle‐regulating hormones within the myostatin–activin–follistatin–IGF‐1 (MAFI) axes.
Methods
Forty‐eight adults with obesity were randomized to lorcaserin (10 mg twice daily) or placebo for 6 months in a double‐blind trial. Regional body composition, hormones and lipidomics were assessed. Changes were analysed using linear mixed models with fixed effects for time, treatment and interaction. Adjusted deltas and endpoints were compared by analysis of covariance controlling for baseline body mass index. Lipidomic profiles were analysed using principal component and partial least‐squares discriminant analyses.
Results
Lorcaserin reduced total body weight (time*treatment, p = 0.004). Adjusted delta and endpoint comparisons showed reductions in total body ( p = 0.031) and abdominal fat mass ( p = 0.002). Lipidomic assessments revealed primarily lower levels of triglyceride‐rich lipoproteins with treatment. No significant changes in MAFI axes components were detected in linear mixed models.
Conclusions
Lorcaserin treatment was associated with greater abdominal fat mass loss, favourable lipid profile changes, while MAFI components remained largely unaffected. Lorcaserin may improve cardiometabolic health primarily through reductions in central adiposity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.
- Department of Medicine, Boston VA Healthcare System, Boston, Massachusetts, USA.
ORCID-Profile: Arantxa Ramirez-Cisneros, Valeria Gutierrez de Piñeres, Claudia S Tamayo-Torres, Christos S Mantzoros
Förderung
- Boehringer Ingelheim
- NIH HHS
- Massachusetts Life Sciences Center
Zitieren
APA
Ramirez-Cisneros, A., Gutierrez de Piñeres, V., Tamayo-Torres, C. S., Stefanakis, K., Angelidi, A. M., Fu, L., Anastasiou, G., & Mantzoros, C. S. (2026). Lorcaserin induces abdominal fat loss with associated improvements of the circulating metabolome/lipidome and no changes in the myostatin–activin–follistatin– IGF ‐1 axes: A 6‐month long randomized placebo‐controlled clinical trial. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.70496
Vancouver
Ramirez-Cisneros A, Gutierrez de Piñeres V, Tamayo-Torres CS, Stefanakis K, Angelidi AM, Fu L, et al. Lorcaserin induces abdominal fat loss with associated improvements of the circulating metabolome/lipidome and no changes in the myostatin–activin–follistatin– IGF ‐1 axes: A 6‐month long randomized placebo‐controlled clinical trial. Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.70496
BibTeX
@article{RamirezCisneros2026,
author = {Ramirez-Cisneros, Arantxa and Gutierrez de Piñeres, Valeria and Tamayo-Torres, Claudia S and Stefanakis, Konstantinos and Angelidi, Angeliki M and Fu, Lynn and Anastasiou, Georgia and Mantzoros, Christos S},
title = {Lorcaserin induces abdominal fat loss with associated improvements of the circulating metabolome/lipidome and no changes in the myostatin–activin–follistatin– IGF ‐1 axes: A 6‐month long randomized placebo‐controlled clinical trial},
journal = {Diabetes, Obesity and Metabolism},
year = {2026},
doi = {10.1111/dom.70496}
}
EUVIMED